For
the quarter ending June 2022, consolidated net sales (including other operating income) of Dr Lal Pathlabs has declined 17.13% to Rs 502.7 crore compared to quarter ended june 2021. Operating profit margin has declined from 31.16% to 23.37%, leading to 37.83% decline in operating profit to Rs 117.50 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 23.92% to 22.72%. Employee cost increased from 14.24% to 19.26%. Other expenses rose from 30.68% to 34.65%. Selling and administration expenses fell from 15.18% to 13.85%. Other income fell 41.13% to Rs 8.3 crore. PBIDT fell 38.06% to Rs 125.8 crore. Provision for interest rose 84.78% to Rs 8.5 crore.
PBDT fell 40.91% to Rs 117.3 crore. Provision for depreciation rose 86.98% to Rs 35.9 crore.
Profit before tax down 54.60% to Rs 81.40 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 23.2 crore, compared to Rs 45.6 crore. Effective tax rate was 28.50% compared to 25.43%.
Minority interest decreased 80% to Rs 0.50 crore. Net profit attributable to owners of the company decreased 56.02% to Rs 57.70 crore. Promoters’ stake was 55.05% as of 30 June 2022 ,compared to 55.23% as of 30 June 2021 .
Full year results analysis.
Net sales (including other operating income) of Dr Lal Pathlabs has increased 32.01% to Rs 2087.4 crore. Operating profit margin has declined from 27.59% to 26.86%, leading to 28.51% rise in operating profit to Rs 560.70 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 25.12% to 24.06%. Employee cost increased from 17.31% to 17.48%. Other expenses rose from 29.98% to 31.59%. Selling and administration expenses rose from 12.92% to 13.63%. Other income rose 2.34% to Rs 52.5 crore. PBIDT rose 25.76% to Rs 613.2 crore. Provision for interest rose 88.75% to Rs 30.2 crore. Loan funds rose to Rs 393.80 crore as of 31 March 2022 from Rs 40.30 crore as of 31 March 2021. Inventories rose to Rs 52.40 crore as of 31 March 2022 from Rs 42.60 crore as of 31 March 2021. Sundry debtors were higher at Rs 85.40 crore as of 31 March 2022 compared to Rs 66.70 crore as of 31 March 2021. Cash and bank balance declined from Rs 926.00 crore as of 31 March 2021 to Rs 617.60 crore as of 31 March 2022. Investments rose to Rs 65.50 crore as of 31 March 2022 from Rs 59.30 crore as of 31 March 2021 .
PBDT rose 23.62% to Rs 583 crore. Provision for depreciation rose 40.03% to Rs 108.1 crore. Fixed assets increased to Rs 429.80 crore as of 31 March 2022 from Rs 371.50 crore as of 31 March 2021. Intangible assets increased from Rs 85.40 crore to Rs 960.50 crore.
Profit before tax grew 20.41% to Rs 474.90 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 124.6 crore, compared to Rs 97.9 crore. Effective tax rate was 26.24% compared to 24.82%.
Minority interest increased 12.24% to Rs 5.50 crore. Net profit attributable to owners of the company increased 18.24% to Rs 344.80 crore.
Equity capital stood at Rs 83.30 crore as of 31 March 2022 to Rs 83.30 crore as of 31 March 2021. Per share face Value remained same at Rs 10.00.
Promoters’ stake was 55.23% as of 31 March 2022 ,compared to 55.23% as of 31 March 2021 .
Cash flow from operating activities increased to Rs 446.70 crore for year ended March 2022 from Rs 398.20 crore for year ended March 2021. Cash flow used in acquiring fixed assets during the year ended March 2022 stood at Rs 476.10 crore, compared to Rs 59.60 crore during the year ended March 2021.
Other Highlights
Board of Directors have declared an
interim dividend of Rs 6 per equity share (60% on a face value of Rs 10 per
share) for the FY 2022. Record date for the purpose is 9th Aug 2022.
Covid and Allied
contributed 4% to Revenue in Q1 FY23.
In Q1 FY23, non-COVID
business grew by 25% on YoY basis and Covid & Allied business fell by 90.5%
on YoY.